Bantovet-CL15 gm

Bantovet-CL is a topical combination product indicated for the treatment of superficial fungal skin infections that are accompanied by significant inflammation. Its approved and evidence-supported uses include:

• Established/approved use: Short-term treatment of inflammatory tinea corporis (ringworm of the body), tinea cruris (jock itch), and tinea pedis (athlete's foot) caused by susceptible dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in patients with a clinically significant inflammatory component.
• Not indicated for tinea versicolor, uncomplicated (non-inflamed) fungal infections, diaper dermatitis, or as first-line therapy for candidal skin infections without inflammation — a corticosteroid-free antifungal alone is generally preferred once inflammation subsides or for infections without significant inflammation.

Bantovet-CL should only be used for the initial, more severely inflamed phase of the infection; therapy is usually switched to a topical antifungal alone once inflammation has improved.

Each formulation of Betamethasone + Clotrimazole combines a corticosteroid and an antifungal agent in a cream, ointment, or lotion base. Common Bangladesh market strengths include:

• Betamethasone (as dipropionate) 0.05% + Clotrimazole 1% — cream
• Betamethasone (as dipropionate) 0.1% + Clotrimazole 1% — ointment

Exact strength and base (cream/ointment/lotion) vary by brand; always check the product label of the specific brand dispensed.

Bantovet-CL is a fixed-dose topical combination of a mid-to-high potency synthetic corticosteroid (betamethasone, usually as the dipropionate ester) and a broad-spectrum imidazole antifungal (clotrimazole). It is formulated for dermatological use to relieve inflammation, itching, and redness while simultaneously treating the underlying dermatophyte or yeast infection responsible for the symptoms.

This combination is intended for short, defined courses of therapy rather than long-term or maintenance use.

Bantovet-CL belongs to the therapeutic class of topical corticosteroid + imidazole antifungal combinations, used in dermatology for inflamed superficial fungal skin infections.

Betamethasone + Clotrimazole combines two agents with complementary mechanisms:

• Betamethasone dipropionate is a synthetic fluorinated corticosteroid that binds intracellular glucocorticoid receptors, inducing anti-inflammatory, antipruritic, and vasoconstrictive effects by suppressing the release of inflammatory mediators (cytokines, prostaglandins) and reducing local edema, erythema, and itching.
• Clotrimazole is an imidazole derivative that acts by inhibiting cytochrome P450-dependent 14-alpha-demethylase, blocking conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane structure and function, giving fungistatic (and at higher concentrations, fungicidal) activity against dermatophytes, yeasts (including Candida species), and some other fungi.

Together, Betamethasone + Clotrimazole provides rapid symptomatic relief from inflammation while treating the causative fungal organism.

Bantovet-CL is for external (topical) use on the skin only.

• Wash and dry the affected area gently before application (unless directed otherwise).
• Apply a thin layer and rub in gently.
• Wash hands after application unless the hands are the area being treated.
• Do not apply an occlusive (airtight) dressing or bandage over the treated area unless specifically instructed by a physician, as this increases absorption and side-effect risk.
• Avoid contact with the eyes, mouth, and open wounds.
• Do not apply to the face, groin, or underarms for prolonged periods unless directed by a physician.

Because Bantovet-CL is applied topically and systemic absorption is normally minimal, clinically significant drug interactions are uncommon. However:

• Other topical corticosteroids or occlusive dressings used concurrently on the same or overlapping skin areas can increase systemic absorption of betamethasone, raising the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression (see Precautions and Warnings).
• Extensive application over large body surface areas, broken skin, or for prolonged periods may increase systemic exposure enough to theoretically interact with other systemic corticosteroids or drugs affected by increased cortisol-like activity (e.g., worsened glycemic control in patients on antidiabetic medicines).

Inform your physician or pharmacist about all other topical or systemic medicines being used before starting Bantovet-CL.

Most side effects of Bantovet-CL are local and mild, occurring at the site of application:

• Common: burning, stinging, itching, redness, dryness, or irritation at the application site.
• Less common: skin thinning (atrophy), stretch marks (striae), visible small blood vessels (telangiectasia), lightening of skin color (hypopigmentation), contact dermatitis, folliculitis, and secondary skin infection.
• Rare, with prolonged or extensive use: systemic corticosteroid effects including HPA-axis suppression, Cushingoid features (moon face, weight gain), elevated blood glucose, and in children, growth suppression — see Precautions and Warnings and Use in Special Populations.

Discontinue use and consult a physician if irritation, sensitization, or worsening of the skin condition occurs.

Pregnancy: There are no adequate, well-controlled studies of Bantovet-CL in pregnant women. Topical corticosteroids can be systemically absorbed and may be associated with fetal harm when used in large amounts or for prolonged periods during pregnancy in animal studies. Bantovet-CL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under medical supervision, using the smallest effective amount for the shortest possible time.

Lactation: It is not known whether topical betamethasone is absorbed and excreted in human milk in clinically significant amounts. As a precaution, avoid applying Bantovet-CL to the breast/nipple area before breastfeeding, and use only if clearly needed, on the advice of a physician.

• Not for prolonged or extensive use: Bantovet-CL should be used for the shortest duration and smallest area needed. Prolonged use, use over large body surface areas, use under occlusive dressings, or use on broken/damaged skin increases systemic absorption of betamethasone and the risk of HPA-axis suppression, which is a greater risk in children due to their higher skin-surface-to-body-weight ratio.
• Local skin changes: Avoid prolonged use on the face, groin, axillae, or other skin folds, as these areas are more prone to skin thinning (atrophy), striae, and telangiectasia with corticosteroid use.
• Masking or worsening infection: If used without adequate antifungal coverage for the specific causative organism, the corticosteroid component of Bantovet-CL may suppress the inflammatory signs of infection while the underlying fungal (or a coexisting bacterial/viral) infection persists or worsens. Clinical improvement should be reassessed regularly.
• Avoid the eyes: Do not allow Bantovet-CL to contact the eyes; if accidental contact occurs, rinse thoroughly with water.
• Hypersensitivity/contact sensitization: Discontinue immediately if signs of irritation, allergic contact dermatitis, or sensitization develop.
• Diabetic patients: Extensive or prolonged application may raise blood glucose levels; monitor as advised by a physician.
• Not for diaper dermatitis or use under occlusive diapers/plastic pants in infants.

Topical overdose of Bantovet-CL (from excessive amounts, prolonged use, or use over large areas) can lead to systemic corticosteroid effects such as HPA-axis suppression, Cushingoid features, elevated blood glucose, and, particularly in children, growth suppression. If accidental oral ingestion occurs, or if signs of excessive systemic absorption develop, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt to manage a suspected overdose at home without professional guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep the tube/container tightly closed and out of reach of children.

• Pediatric use: Not recommended in children under 17 years of age. Safety and efficacy of Bantovet-CL have not been established in this population, and children are at greater risk of HPA-axis suppression and systemic corticosteroid side effects due to a larger skin-surface-area-to-body-weight ratio (see Precautions and Warnings).
• Elderly: No specific dose adjustment is established, but elderly patients may have thinner skin and could be more susceptible to local corticosteroid-related skin atrophy; use the minimum effective amount.
• Renal/hepatic impairment: No formal dose adjustment studies exist for topical use, as systemic absorption is normally minimal; however, caution is advised with extensive or prolonged application in these patients.
• Immunocompromised patients: Use with caution, as the corticosteroid component may mask signs of worsening infection.

Treatment with Bantovet-CL should be limited to the shortest effective duration:

• Tinea cruris and tinea corporis: up to 2 weeks.
• Tinea pedis: up to 4 weeks.

If there is no improvement within the first 1–2 weeks, or if the condition worsens, treatment should be reassessed by a physician. Use beyond 4 weeks is not recommended due to increasing risk of local and systemic corticosteroid side effects.

Topical corticosteroid (betamethasone) combined with an imidazole antifungal (clotrimazole)

Betamethasone + Clotrimazole works through two complementary mechanisms: betamethasone dipropionate binds glucocorticoid receptors to suppress inflammatory mediator release, reducing redness, swelling, and itching; clotrimazole inhibits fungal cytochrome P450 14-alpha-demethylase, blocking ergosterol synthesis and disrupting the fungal cell membrane, producing fungistatic/fungicidal activity against the causative dermatophyte or yeast.

C

Bantovet-CL is not recommended for use in children under 17 years of age. Clinical studies have shown that children are more susceptible than adults to HPA-axis suppression and other systemic corticosteroid adverse effects following topical corticosteroid application, because of a larger skin-surface-area-to-body-weight ratio. Safety and efficacy in this age group have not been established. If a fungal infection with inflammation requires treatment in a child, a physician should be consulted for an age-appropriate alternative.